09.12.2014 • News

Eastman Completes $2.8 Billion Takeover of Taminco

US chemical producer Eastman has completed its acquisition of compatriot Taminco for $2.8 billion in cash and assumed debt of an estimated $1 billion.

Eastman said the acquired assets should be accretive to earnings in 2015.

Stockholders of Taminco, a major producer of alklylamines and alkylamine derivatives, will receive $26 in cash for each of their Taminco common shares. The stock has been delisted from trading on the New York Stock Exchange.

Taminco's Specialty Amines and Crop Protection businesses will be operated as part of Eastman's Additives & Functional Products segment. Its Functional Amines business will be operated as part of the Tennessee-based chemical company's Specialty Fluids & Intermediates segment.

Mark Costa, Eastman's chairman and CEO, said: "Taminco's world-class alkylamine technology platform and strong presence in attractive niche end markets will further strengthen our position as a leading specialty chemical company." He added that Eastman is "committed to successful integration of Taminco and looks forward to delivering the projected synergies of this transaction."

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read